Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

J. A. Green; E. M J J Berns; C. Coens; I. van Luijk; J. Thompson-Hehir; P. van Diest; R. H M Verheijen; M. van de Vijver; P. van Dam; G. G. Kenter; W. Tjalma; P. C. Ewing; I. Teodorovic; I. Vergote; M. E L van der Burg

doi:10.1016/j.ejca.2006.06.015

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

J. A. Green, E. M J J Berns, C. Coens, I. van Luijk, J. Thompson-Hehir, P. van Diest, R. H M Verheijen, M. van de Vijver, P. van Dam, G. G. Kenter, W. Tjalma, P. C. Ewing, I. Teodorovic, I. Vergote, M. E L van der Burg

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.

Original language	English (US)
Pages (from-to)	2539-2548
Number of pages	10
Journal	European Journal of Cancer
Volume	42
Issue number	15
DOIs	https://doi.org/10.1016/j.ejca.2006.06.015
State	Published - Oct 2006
Externally published	Yes

Keywords

Bcl-2
DNA ploidy
Immunohistochemistry
MIB-1
Morphometry
P21
P53
Prognosis
Suboptimally debulked advanced ovarian cancer

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.ejca.2006.06.015

Cite this

Green, J. A., Berns, E. M. J. J., Coens, C., van Luijk, I., Thompson-Hehir, J., van Diest, P., Verheijen, R. H. M., van de Vijver, M., van Dam, P., Kenter, G. G., Tjalma, W., Ewing, P. C., Teodorovic, I., Vergote, I., & van der Burg, M. E. L. (2006). Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). European Journal of Cancer, 42(15), 2539-2548. https://doi.org/10.1016/j.ejca.2006.06.015

Green, JA, Berns, EMJJ, Coens, C, van Luijk, I, Thompson-Hehir, J, van Diest, P, Verheijen, RHM, van de Vijver, M, van Dam, P, Kenter, GG, Tjalma, W, Ewing, PC, Teodorovic, I, Vergote, I & van der Burg, MEL 2006, 'Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)', European Journal of Cancer, vol. 42, no. 15, pp. 2539-2548. https://doi.org/10.1016/j.ejca.2006.06.015

@article{332e338568ce4f319b95bded3fa9f1ab,

title = "Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)",

abstract = "Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.",

keywords = "Bcl-2, DNA ploidy, Immunohistochemistry, MIB-1, Morphometry, P21, P53, Prognosis, Suboptimally debulked advanced ovarian cancer",

author = "Green, {J. A.} and Berns, {E. M J J} and C. Coens and {van Luijk}, I. and J. Thompson-Hehir and {van Diest}, P. and Verheijen, {R. H M} and {van de Vijver}, M. and {van Dam}, P. and Kenter, {G. G.} and W. Tjalma and Ewing, {P. C.} and I. Teodorovic and I. Vergote and {van der Burg}, {M. E L}",

year = "2006",

month = oct,

doi = "10.1016/j.ejca.2006.06.015",

language = "English (US)",

volume = "42",

pages = "2539--2548",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "15",

}

TY - JOUR

T1 - Alterations in the p53 pathway and prognosis in advanced ovarian cancer

T2 - A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

AU - Green, J. A.

AU - Berns, E. M J J

AU - Coens, C.

AU - van Luijk, I.

AU - Thompson-Hehir, J.

AU - van Diest, P.

AU - Verheijen, R. H M

AU - van de Vijver, M.

AU - van Dam, P.

AU - Kenter, G. G.

AU - Tjalma, W.

AU - Ewing, P. C.

AU - Teodorovic, I.

AU - Vergote, I.

AU - van der Burg, M. E L

PY - 2006/10

Y1 - 2006/10

N2 - Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.

AB - Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.

KW - Bcl-2

KW - DNA ploidy

KW - Immunohistochemistry

KW - MIB-1

KW - Morphometry

KW - P21

KW - P53

KW - Prognosis

KW - Suboptimally debulked advanced ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=33748959684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748959684&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2006.06.015

DO - 10.1016/j.ejca.2006.06.015

M3 - Article

C2 - 16965910

AN - SCOPUS:33748959684

SN - 0959-8049

VL - 42

SP - 2539

EP - 2548

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 15

ER -

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this